These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30254953)

  • 41. Impact of Uterine Adenomyosis on Pregnancy Outcomes in Women Undergoing
    Zhang J; Hu L; Bu Z; Sun Y
    Front Endocrinol (Lausanne); 2021; 12():655803. PubMed ID: 34489861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of High-Intensity Focused Ultrasound Combined With GnRH-a for Adenomyosis: A Systematic Review and Meta-Analysis.
    Pang LL; Mei J; Fan LX; Zhao TT; Li RN; Wen Y
    Front Public Health; 2021; 9():688264. PubMed ID: 34485218
    [No Abstract]   [Full Text] [Related]  

  • 43. Late presentation of extrauterine adenomyomas after laparoscopic morcellation at hysterectomy: a case report.
    Zaki MN; Gheewale AMF; Ibrahim N; Elrahman IA
    BMC Womens Health; 2021 Jul; 21(1):269. PubMed ID: 34233685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adenomyosis and Infertility-Review of Medical and Surgical Approaches.
    Szubert M; Koziróg E; Olszak O; Krygier-Kurz K; Kazmierczak J; Wilczynski J
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33573117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations.
    Inoue S; Hirota Y; Ueno T; Fukui Y; Yoshida E; Hayashi T; Kojima S; Takeyama R; Hashimoto T; Kiyono T; Ikemura M; Taguchi A; Tanaka T; Tanaka Y; Sakata S; Takeuchi K; Muraoka A; Osuka S; Saito T; Oda K; Osuga Y; Terao Y; Kawazu M; Mano H
    Nat Commun; 2019 Dec; 10(1):5785. PubMed ID: 31857578
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Progress on medical treatment in the management of adenomyosis].
    Baboo KD; Chen Z; Zhang X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 Apr; 48(2):142-147. PubMed ID: 31309751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy, Adverse Events, and Challenges of Dienogest in the Management of Symptomatic Adenomyosis: A Comparison with Different Hormonal Treatments.
    Kobayashi H
    Gynecol Obstet Invest; 2023; 88(2):71-80. PubMed ID: 36682346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review.
    Lethaby A; Vollenhoven B; Sowter M
    BJOG; 2002 Oct; 109(10):1097-108. PubMed ID: 12387461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of Hormonal Therapies for Decreasing Uterine Volume in Patients with Adenomyosis.
    Matsushima T; Akira S; Fukami T; Yoneyama K; Takeshita T
    Gynecol Minim Invasive Ther; 2018; 7(3):119-123. PubMed ID: 30254953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy of dienogest versus gonadotropin-releasing hormone agonist combined with dienogest sequential therapy in the treatment of adenomyosis].
    Zhang HY; Zhu S; Xu W; Wang AQ; Wang XL
    Zhonghua Fu Chan Ke Za Zhi; 2022 Nov; 57(11):856-863. PubMed ID: 36456483
    [No Abstract]   [Full Text] [Related]  

  • 51. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
    Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
    Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
    Matsushima T; Akira S; Yoneyama K; Takeshita T
    Gynecol Endocrinol; 2020 Jun; 36(6):521-524. PubMed ID: 31661345
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
    Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
    J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
    Miao J; Lu J; Tang J; Lu P
    Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
    [No Abstract]   [Full Text] [Related]  

  • 55. Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use.
    Matsushima T; Akira S; Asakura H; Takeshita T
    Clin Exp Obstet Gynecol; 2017; 44(1):143-145. PubMed ID: 29714885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of medical therapy in the management of uterine adenomyosis.
    Vannuccini S; Luisi S; Tosti C; Sorbi F; Petraglia F
    Fertil Steril; 2018 Mar; 109(3):398-405. PubMed ID: 29566852
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.